Biotechnology company
Appears in 1 story
Sponsor of the CMP-002 trial
About 700 people worldwide have a confirmed diagnosis of SYNGAP1-related disorder. It causes intellectual disability and seizures, and no drug has ever been approved to treat it. On July 27, 2026, that changed at the edges: Australia's drug regulator cleared the first medicine designed to fix the disorder's root cause to be tested in people.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
